Contemporary management of diffuse large B-cell lymphoma in Japan

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Diffuse large B-cell lymphoma (DLBCL) management varies globally.
• Japan's universal healthcare system facilitates access to novel DLBCL treatments.
• High incidence of DLBCL in older adults necessitates specialized care.

Purpose of the Study:

• To review current DLBCL diagnosis and treatment trends in Japan.
• To highlight DLBCL management in older adults, CD5-positive DLBCL, and intravascular large B-cell lymphoma (IVLBCL).
• To assess the role of novel therapies like polatuzumab vedotin, CAR-T, and bispecific antibodies.

Main Methods:

• Literature review of recent DLBCL studies and clinical trials in Japan.
• Analysis of treatment patterns considering Japan's healthcare environment.
• Focus on specific DLBCL subtypes and patient demographics.

Main Results:

• Polatuzumab vedotin is a common first-line option for advanced DLBCL.
• Geriatric assessment is crucial for older DLBCL patients.
• CAR-T and bispecific antibodies show promise in relapsed/refractory settings.
• Specific strategies for CD5+ DLBCL and IVLBCL require further investigation.

Conclusions:

• Accurate diagnosis and emerging genomic assays are key for precision DLBCL treatment.
• Careful consideration of polatuzumab vedotin's role is needed.
• Geriatric assessment is vital for elderly DLBCL patients.
• Novel therapies like CAR-T and bispecific antibodies are expanding treatment options for relapsed/refractory DLBCL, necessitating cost-effectiveness evaluations.